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Abstract
Background: Human endometrium with consecutive regeneration capability
undergoes monthly hormonal changes for probable implantation, which confirms
the presence of the cells in the basalis layer known as stem cell.
Objective: Previously, we reported the isolation and culture of the mesenchymal-like
cells from human endometrium. In this study, we evaluated the biological and stemness
characteristics of these cells.
Materials and Methods: The characterization of Yazd human endometrial-
derived mesenchymal stem/stromal cells (YhEnMSCs) was assessed using
immunofluorescence (IF) staining for CD105, VIMENTIN, and FIBRONECTIN as
markers and RT-PCR for CD166, CD10, CD105, VIMENTIN, FIBRONECTIN, MHCI, CD14,
and MHCII genes. Flow cytometry (FACS) was performed for CD44, CD73, CD90,
and CD105 markers. Moreover, the differentiation capacity of the YhEnMSCs to the
osteoblast and adipocytes was confirmed by Alizarin Red and Oil Red staining.
Results: YhEnMSCs expressed CD105, VIMENTIN, FIBRONECTIN, CD44, CD73, and
CD90 markers and CD166, CD10, CD105, VIMENTIN, FIBRONECTIN, and MHCI, but,
did not express CD14, MHCII.
Conclusion: Our data confirm previous reports by other groups indicating the
application of endometrial cells as an available source of MSCs with self-renewal and
differentiation capacity. Accordingly, YhEnMSCs can be used as a suitable source for
cell-based therapies.
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1. Introduction
Human endometrium is a unique tissue that
undergoes a monthly cycle of regeneration
and regression with each menstrual cycle of
women. It regenerates the functionalis layer which
is essential for a successful implantation; this
procedure depends on the presence of the stem
cell population that resides in the basalis layer of
the endometrium (1, 2). Recently, high expression
of OCT-4, SOX-2, NANOG, and REX-1 as stemness
genes has been reported in the proliferative phase
comprised of secretory and menstrual phases (3).
The first evidence demonstrating the existence of
the endometrial stem cells (EnSCs) was reported
in 2004 (4). Following that, reports confirmed the
mesenchymal stem cell (MSCs) properties of the
endometrial-derived mesenchymal stem/stromal
cells (EnMSCs) including self-renewal, proliferation,
clonogenicity, and differentiation into different
mesodermal cell lineages such as chondrocytes,
osteocytes, adipocytes, and smooth muscle
cells (5-9). Also, for the first time, Fayazi and
colleagues demonstrated the differentiation ability
of EnMSCs into neural and oligodendrocyte
lineages (10). They used retinoic acid (RA)
supplemented with epithelial growth factor (EGF)
and basic fibroblast growth factor (bFGF) for
the differentiation procedure and postulated
that this potential depends on the essential role
of RA in combination with growth factors (10).
Similarly, other studies, besides clonality and
multilineage differentiation potential, showed
another MSC characteristics of endometrial-
derived stromal cells such as the expression of
CD146, CD105, CD90, CD73 as specific MSCs
markers and the lack of hematopoietic markers
expression including CD34 and CD14 (10, 11).
Recently, reports confirmed expression of specific
MSCs markers including CD73, CD105, CD29,
CD44, differentiation potential into mesodermal
cell lineages and also, cytokines secretion into
isolated MSCs from menstrual blood (9). Therefore,
owing to this potential, EnMSCs could be used
as an appropriate source in the regenerative
medicine and subsequent cell therapy for treating
uterine-factor infertile patient in the future (1, 2, 7).
In this study, isolated and cultured spindle-shape
human EnMSCs confirmed MSCs’ properties
by expression of specific markers including
CD105, CD44, CD73, CD90, VIMENTIN, and
FIBRONECTIN using immunofluorescence (IF)
and flow cytometry (FACS) techniques. Moreover,
reverse transcription-polymerase chain reaction
(RT-PCR) was performed for CD166, CD10, CD105,
VIMENTIN, FIBRONECTIN, MHCI, CD14, MHCII
genes. Thereafter, osteogenic and adipogenic
differentiation capability of the multipotent-derived
EnMSCs were examined using Alizarin Red and Oil
Red O staining, respectively.
2. Materials and Methods
The chemicals used in this lab resources study
were purchased from Sigma Aldrich (Poole, UK),
while the culture media and supplements were
purchased from Invitrogen, Gibco (UK), unless
otherwise stated.
2.1. Samples collection and
endometrial tissue preparation
The collection of human endometrial tissues
was performed at the Stem Cell Biology Research
Center, Yazd Reproductive Sciences Institute,
following a hysterectomy procedure of women
aged 30-42 yr (n = 4) with polycystic ovarian
syndrome (PCOs). At the beginning of the isolation
of human endometrial cells for culture preparation,
first, human endometrial tissues were washed
in the Dulbecco’s phosphate-buffered saline
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(PBS; Biowest) and dissected from myometrium
layer. Next, tissue fragments were dissociated
into single-cell suspension with mechanical
and enzymatic digestion. Human EnMSCs and
isolated cells were then cultured in the flasks
(Falcon, USA) containing Dulbecco’s modified
Eagle’s medium (DMEM) supplemented with 1 µl/ml
penicillin/streptomycin and 10% fetal bovine serum
(FBS; all from Gibco, Grand Island, NY) and finally
incubated in a humidified atmosphere at 37°C and
5% CO2 as described previously (12).
2.2. Immuno fluorescence localization
for MSCs markers
IF staining was performed for characterization.
For the IF technique, cells were washed thrice with
PBS, then fixed with 4% paraformaldehyde (Sigma-
Aldrich, St. Louis, MO, USA) solution for 15 min at
room temperature. Next, the cells were washed
twice for 5 min in PBS and treated with 0.1% Triton
X-100 (Sigma, USA) for 5 min. The cells were then
incubated for 30 min with PBS supplemented with
10% FBS as blocking solution for the inhibition of
the nonspecific binding 24 hr before incubation
with primary antibodies (CD105, VIMENTIN, and
FIBRONECTIN) at 4°C. Incubation with secondary
antibodies was performed for 1 hr at 37°C. Finally,
inverted fluorescence microscopy (Olympus IX-71,
Tokyo, Japan) was used for evaluating samples
with appropriate excitation optics (13). It should be
noted that negative controls were only incubated
with secondary antibodies. Table I presents the
information about the antibodies.
2.3. RNA extraction, complementary
DNA (cDNA) synthesis, and reverse-
transcription PCR
Total RNA of the human EnMSCs was extracted
by TRI Reagent (Sigma-Aldrich, USA) according to
the manufacturer’s instructions. The extracted RNA
was then treated with DNase I (Invitrogen, USA),
and complementary DNA (cDNA) synthesize was
performed using the (Thermo scientific, USA) kit
according to themanufacturer’s protocol. Following
that, the cDNA was subjected to RT-PCR in a 20-
µl final reaction volume including 1 µl cDNA, 0.5
µl of each primer (20 mM), 6 µl dH2O, and 12 µl
Taq DNA Polymerase Master Mix RED (Ampliqon,
USA). The β2-microglobulin (β2M) gene was used
as an internal control and target genes CD166,
CD10, CD105, VIMENTIN, FIBRONECTIN, MHCI,
CD14, MHCII were evaluated. The amplification
plan was as follows: initial denaturation step at
94°C for 5 min, followed by another denaturation
step at 94°C for 30 sec, annealing step at 58°C
(CD166, CD10, CD105, VIMENTIN, FIBRONECTIN,
MHCI, CD14, and MHCII), 60°C (CD105 and β2M)
for 30 sec, an extension for 30 sec at 72°C for 40
cycles, and a final extension performed in two steps
at 72°C for 5 min and 4°C for 1 min. PCR products
were detected on 2%agarose gels electrophoresis.
Table II presents the summary information of the
primers.
2.4. Characterization of Yazd human
endometrial-derived mesenchymal
stem/stromal cells (YhEnMSCs) using
FACS
For the characterization of cultured cells
using FACS, YhEnMSCs were washed with PBS
containing 0.5% FBS after dissociation using
0.25% trypsin EDTA enzyme. Primary antibodies
including CD44 (Monoclonal Antibody; FITC,
eBioscience), CD73 (Monoclonal Antibody; PerCP,
BD Bioscience), CD90 (Monoclonal Antibody;
FITC, eBioscience), and CD105 (Monoclonal
Antibody; PerCP, BD Bioscience) were used for
30 min and stored at 4°C. Next, the EnMSCs were
incubated by appropriate fluorescent conjugated
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secondary antibodies in dark for 60 min at 4°C.
While samples were analyzed on BD FACSCalibure
(BD biosciences, San Jose, CA, USA), data analysis
was performed using the FlowJo 7.6 software.
2.5. Osteogenic and adipogenic
differentiation of YhEnMSCs
To prove the stemness of the YhEnMSCs,
osteogenic and adipogenic differentiation were
induced in the EnMSCs. Osteogenic differentiation
was performed using 3 × 103 cells/cm2 which was
cultured in DMEM + 10% FBS. At approximately 70%
confluency, the osteogenic medium containing
DMEM was supplemented with 50 mg/mL ascorbic
acid 2-phosphate, 10 nM dexamethasone, and
10 mM b-glycerophosphate was replaced with
DMEM + 10% FBS. The osteogenic medium
was changed every three days for 21 days.
After washing of the cells twice using PBS and
fixation by paraformaldehyde 4% (Sigma) for 30
min, matrix mineralization was stained by 40
mM Alizarin Red for 15 min. For adipogenesis,
EnMSCs were cultured with differentiation medium
containing DMEM supplemented with 50 mg/mL
indomethacin and 100 nM dexamethasone for 21
days which was changed every three days. For the
detection of lipid droplets, cells were stained by
Oil Red O. These differentiation experiments were
performed in triplicate (13).
2.6. Karyotype analysis of YhEnMSCs
The chromosomal content of the YhEnMSCs
was determined by standard G-banding procedure
which has been described previously (14). G-
bandings were analyzed through light microscopy
(Ziess, Germany, Axiophot) using applied spectral
imaging software.
Table I. List of antibodies used for IF
Primary antibody Secondary antibody
Name Dilution Catalog number Type Dilution Catalog number
CD105/EGLN1 1:100 Abcam ab11414 Anti-mouse IgG (FITC) 1:100 Abcam ab6785
VIMENTIN 1:100 Millipore AB573 Anti-Chicken IgY (TR) 1:100 Abcam ab6751
FIBRONECTIN 1:200 Abcam ab6328 Anti-mouse IgG (FITC) 1:100 Abcam ab6785
FITC: Fluorescein isothiocyanate; TRITC; TR: Tetramethylrhodamine
Table II. List of primers used for RT-PCR
Gene Forward primer (5’→3’) Reverse primer (5’→3’) Annealing temp (°C) Prod size (bp)
CD105 CTTGGCCTACAATTCCAGCC CTTGAGGTGTGTCTGGGAGC 60 542
CD166 TCCTGCCGTCTGCTCTTCT TTCTGAGGTACGTCAAGTCGG 58 128
CD10 GGCACCAGAAGAACAGTAGG ATCTCAGCATCAGTCAAAGC 58 269
FIBRONECTIN AGGAAGCCGAGGTTTTAACTG AGGACGCTCATAAGTGTCACC 58 106
VIMENTIN TCTATCTTGCGCTCCTGAAAAACT AAACTTTCCCTCCCTGAACCTGAG 58 270
CD14 CACACTCGCCTGCCTTTTCC GATTCCCGTCCAGTGTCAGG 58 450
MHCI CCTACGACGGCAAGGATTAC TGCCAGGTCAGTGTGATCTC 58 304
MHCII GCCGAGTTCTATCTGAATCCTG TTGCGCAATCCCTTGATGATG 58 629
𝛽2M AGATGAGTATGCCTGCCGTG TGCGGCATCTTCAAACCTC 60 106
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2.7. Ethical consideration
The YhEnMSCs were isolated and cultured after
obtaining fully informed written consent from the
participants prior to the study, in compliance with
the guidelines of the Shahid Sadoughi University
of Medical Sciences Ethical Committee (code:
IR.SSU.REC.1396.186).
3. Results
3.1. Isolation and culture of YhEnMSCs
Monitoring of the cell adherence and growth were
performed 24 hr after the culture by invertedmicroscopy
(Olympus CKX-41, Tokyo, Japan); some of the adherent
cells were detected on the bottom of the flask. During
several passages, homogenous EnMSCs fibroblast-
like cells were observed (12). Moreover, colonies
were formed during the passaging of the cells in
different passage numbers (12). In addition, during the
colony formation, various morphological cell types from
spindle-shaped to triangular patterns could be detected.
3.2. Characterization of YhEnMSCs
using IF
The expression of the specific EnMSC markers was
examined by IF technique with CD105, VIMENTIN, and
FIBRONECTIN antibodies. Human EnMSCswereCD105-
positive (Figures 1A, B, and C), and also, the expression
of the VIMENTIN (Figure 1D, E, and F) and FIBRONECTIN
(Figure 1G, H, and I) markers was detected in the human
EnMSCs.
3.3. Gene expression profile of
YhEnMSCs
Yazd hEnMSCs with normal karyotype (46 XX; Figure
2A) expressed the MSCs genes including CD166, CD10,
CD105, VIMENTIN, FIBRONECTIN, MHCI (Figure 2B).
However, CD14 and MHCII were not expressed (Figure
2B).
3.4. Characterization of YhEnMSCs
using FACS
Yazd EnMSCs expressed CD105, CD90, CD73, and
CD44 as specific MSCs markers using FACS (Figure 3).
3.5. In vitro differentiation of
YhEnMSCs
Matrix mineralization and accumulation of the lipid
droplets after differentiation into osteogenic (Figure
4A) and adipogenic (Figure 4B) lineages were shown
respectively.
Figure 1. Characterization of YhEnMSCs using IF staining. CD105 (A), DAPI (B), and CD105 and DAPI merged (C). VIMENTIN (D),
DAPI (E), and VIMENTIN and DAPI merged (F). FIBRONECTIN (G), DAPI (H), and FIBRONECTIN and DAPI merged (I). Scale bars:
A-F: 200 µm, G-I: 100 µm.
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Figure 2. A normal, diploid 46, XX karyotype for the YhEnMSCs (A) was shown using G-binding. Further characterization of
YhEnMSCs using RT-CR. Yazd hEnMSCs revealed their gene expression profile for specific genes such as CD166, CD10, CD105,
VIMENTIN, FIBRONECTIN, and MHCI. Cells did not express CD14 and MHCII (B).
Figure 3. Characterization of YhEnMSCs using FACS assessment indicated that YhEnMSCs were positive for CD44, CD73, CD90,
and CD105.
Figure 4. Differentiation capacity of YhEnMSCs. Osteogenic (A) and adipogenic (B) differentiation of YhEnMSCs was confirmed
by Alizarin Red and Oil Red staining. Scale bars: 100 µm.
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4. Discussion
Our data confirm the previously reported
findings for the identification of MSCs from human
endometrium using specific genes expression
profiles and markers. Moreover, the cells show
a differentiation capacity to osteoblasts and
adipocytes.
Similar findings reported positive expression of
the MSCs specific markers using FACS analysis
for stromal cells colonies-derived endometrium
including CD29, CD44, CD73, CD105, CD140B
(6). Another study showed positive expression of
CD90 andCD105markers and reported that CD146
was significantly positive in cultured cells which are
known as mesenchymal stromal stem cells marker
(10).
Previously (4, 9), the clonogenicity ability of
the stromal cells derived from endometrium
was confirmed in a similar way as that of the
YhEnMSCs behavior in this study (12). Moreover,
similar to other studies (5-9), we demonstrated
the differentiation potential of YhEnMSCs into
adipogenic and osteogenic lineages.
Interestingly, studies showed
immunomodulatory effects of MSCs due to
lack of MHC class II expression which inhibited
T cell proliferation (15). On the other hand,
MSCs present positive expression of major
histocompatibility complex (MHC) class I during
differentiation into adipogenic, osteogenic, and
chondrogenic lineages that protect them from
Natural killer (NK) cells mechanisms (16). Therefore,
the immunomodulatory feature of MSCs makes
them highly attractive for clinical applications. Our
results showed positive and negative expression
of MHC class I and II, respectively.
For clinical application of hEnMSCs, Zhang
and colleagues reported positive effect of
conditioned medium from human endometrial
mesenchymal stem cells derived from menstrual
blood (MenSCs) on angiogenesis (17). Also,
recently, it was shown that EnMSCs improved
cardiac function in infarcted rat myocardium (18).
Interestingly, Wang and colleagues explored
that MenSCs can be regenerated and could
improve ovarian function in mice with a premature
ovarian failure (19). It should also be noted that
the differentiation potential of EnMSCs can
be used for repairing various types of tissue
injury.
In sum, the isolated YhEnMSCs (12) were
characterized with specific MSCs markers
CD105, CD44, CD73, CD90, VIMENTIN, and
FIBRONECTIN using IF and FACS. In addition, the
gene expression profile of the cells for CD166,
CD10, CD105, VIMENTIN, FIBRONECTIN, MHCI
genes was evaluated using RT-PCR. YhEnMSCs
did not express CD14 and MHCII. Osteogenic
and adipogenic differentiation potential of the
YhEnMSCs was confirmed using Alizarin Red and
Oil Red staining.
5. Conclusion
In conclusion, the endometrial tissue as a part
of uterus with self-renewal and differentiation
capacity that undergoes a cyclical regeneration
every month in normal women’s life span is
a source of MSCs. YhEnMSCs can proliferate
and differentiate into different cell types. Hence,
according to the therapeutic application of these
cells, YhEnMSCs could be used for future novel
therapeutic methods in regenerative medicine for
the treatment of uterine-factor infertile patients
which can lead to recurrent pregnancy loss (RPL)
and finally resolve surrogacy problems.
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